From Discovery To Clinic: Getting Ready For Phase 1


Date: June 15, 2017

Location: TCTLV, Bachar Building, 22 Rothschild / 35, Lilienblum, Tel Aviv 6513316, Israel.

To register for this free event, please click here

From Discovery to Clinic: Getting Ready for Phase 1

Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development.  Addressing issues early and comprehensively in the development life-cycle can result in fewer problems down the line such as escalating timelines, costs and regulatory issues. It is important to leverage the skills and experience of experts and connect the dots between competencies to optimize the development pathway and enable drug candidates to reach their true potential.

This event will focus on a number of key considerations for transitioning a molecule from discovery to phase 1 readiness including active pharmaceutical ingredient and drug product development, clinical study design, and regulatory requirements.

Catalent Event Agenda


Agenda Item



Welcoming refreshments


Opening Welcome

 Liri Benshimol of IATI 

 Louis Weiner of Catalent


Early Development Considerations – At the Interface Between Multiple Disciplines

Dr. Shmuel Ben-Sasson (Mulli) – Professor, Hebrew University, Jerusalem


The Importance of ADME/DMPK Considerations in Early Preclinical Studies Design

Dr. Revital Duvdevani – Dr. Eyal Bressler & Co 


Break & Networking


Proper Formulation Technology Selection

Julien Meissonnier of Catalent


Considerations for Designing Clinical Phase 1 Studies

Malcom Boyce; HMR London


Lunch & Networking

1:1s with experts